Glucotrack (Nasdaq:GCTK) today announced findings from a market research study demonstrating the acceptance of its CBGM concept.
Rutherford, New Jersey-based Glucotrack develops a small device placed under the skin for continuous blood glucose monitoring. It designed the technology to deliver continuous, accurate blood glucose monitoring for up to three years. This would eliminate some of the calibration, comfort and wearability challenges associated with traditional CGM approaches, Glucotrack says.
The study evaluated opinions of the company’s new continuous blood glucose monitor for those with insulin-requiring diabetes. It included 757 respondents with intensive insulin therapy (49% type 1 diabetes and 51% type 2 diabetes). Current CGM users made up 67% of the subjects, followed by non-users (25%) and ex-users (8%). Respondents used various insulin delivery methods (60% MDI, 40% insulin pumps, with 21% using automated insulin delivery).
Of a diverse group of participants, more than 50% of subjects expressed openness to adopting the concept.
Glucotrack said it saw the most interest in the long-term sensor life (the study tested a two-year sensor duration). Subjects also registered interest in the absence of a wearable component and the real-time blood glucose readings provided.
“This market research shows us that there is clear need for innovation in continuous glucose monitoring and that Glucotrack’s innovative approach has tremendous market potential as it addresses unmet needs,” said Paul Goode, President & CEO at Glucotrack. “Our goal has always been to develop innovative solutions that improve the quality of life for people with diabetes. The insights gained from this study will be invaluable as we continue to refine our CBGM technology to better meet the needs of our users.”
Glucotrack’s current pipeline includes a long-term implantable CGM and the new CBGM concept. The company has plans for upcoming human clinical trials later this year.
